implicated in predisposition to Wilms' tumour -may preferentially interact with splicing factors, suggesting a role for WT1 in RNA processing.
Wilms' tumour is one of the most prevalent childhood malignancies, giving rise to nephroblastomas in approximately 1 out of 10 000 children (reviewed in [1] ). Wilms' tumour is also frequently associated with congenital urogenital abnormalities. The genetic basis of Wilms' tumour development is complex, and at least three separate genes are believed to confer predisposition to this form of malignancy. So far, only one such Wilms'-tumour-predisposition gene, called WT1, has been characterized. WT1 is a tumour suppressor gene [2] and is implicated in 10-15 % of Wilms' tumours. Mutations in WT1 can also give rise to syndromes such as Denys-Drash syndrome, which is characterized by glomerulonephropathy, pseudohermaphroditism and Wilms' tumour.
The human WT1 gene was mapped to chromosome 1 lp13 and has been cloned and sequenced [3, 4] . Analysis of null mutant mice shows WT1 is essential for both urogenital development and fetal survival beyond 15 days of gestation. 1WT1 mRNA and protein are expressed in specific cell types at three different stages of nephrogenesis and also in certain cell types of other mesoderm-derived tissues, including the gonad, spleen and the mesothelium. At the same time as these tissues express WT1, they undergo a switch from mesenchymal to epithelial cell types. Wilms' tumour thus provides a clear example of how oncogenesis can arise through a genetic failure in developmental regulation.
The deduced WT1 protein sequence indicates that it may act as a DNA-binding factor. It has four carboxy-terminal Kriippel-type zinc-finger domains and a proline/glutamine-rich transregulatory domain akin to that found in many known transcriptional regulators (Fig. 1) . Zinc finger motifs 2-4 of WT1 are closely related to the three zinc fingers of the transcription factors SP1, EGRI and EGR2. In view of these features of its sequence, it has been widely believed that the WT1 protein acts to regulate transcription of genes required for normal kidney development.
Although no genes regulated by WT1 in vivo have yet been identified, WT1 is known to bind in vitro to the DNA sequence 5'-GCGGGGGCG-3' [5] . This is the consensus binding site for EGR1, and occurs in the promoter region of many genes, including some that are implicated in growth regulation. Data from transient transfection assays indicate that WT1 can repress transcription from promoters containing the EGR1 consensus binding site [1] . Clinical studies have shown that many patients suffering from Denys-Drash syndrome and Wilms' tumour have point mutations or deletions in the zinc-finger regions of WT1 and, in at least some cases, these mutations have been found to affect DNA binding.
Four isoforms of WT1 are formed by alternative RNA splicing (Fig. 1) . These arise from the inclusion or omission of the 17 amino acids encoded by exon 5, amino terminal to the first zinc finger, and the inclusion or omission of the three amino acids lysine-threonine-serine (KTS) between zinc fingers 3 and 4. The insertion of KTS arises through use of an alternative 5' splice site at the end of exon 9. The +KTS isoforms are some fourfold more abundant than the -KTS isoforms. Comparative sequence analysis has shown that WT1 is highly conserved among vertebrates; although the alternative splicing of exon 5 has only been detected in mammals, the alternative splicing of KTS between zinc fingers 3 and 4 is conserved from zebrafish to humans. This strongly indicates that the insertion of KTS is functionally important.
Interestingly, inclusion of KTS between zinc fingers 3 and 4 has been found to change the DNA-binding properties of WT1. It is the -KTS isoforms that specifically bind to the EGR1 consensus sequence, whereas the +KTS isoforms do not strongly bind this sequence, and in comparison show a generally reduced affinity for DNA. Patients with abnormal ratios of the +KTS and -KTS WT1 isoforms can also manifest severe developmental problems, again pointing to the important role of the alternative splicing of the KTS motif. New data from Hastie and coworkers [6] now show that alternative splicing of the KTS motif influences the intranuclear localization of WT1 -the +KTS isoforms associate with components of the pre-mRNA splicing machinery.
Fig. 1.
WT1 is a protein of -53 kDa which has a proline/glutamine-rich domain in the amino-terminal region and four zinc finger domains (red) in the carboxy-terminal region. Four isoforms of WT1 are produced through alternative splicing. This results in either inclusion or omission of exon 5 and of the three amino acids lysine-threonine-serine (KTS) between zinc fingers 3 and 4. The isoform shown includes both the exon-5-encoded and KTS sequences (green).
Larsson et al. [6] used confocal-fluorescence-microscopy analysis to localize WT1 in either fetal kidney or gonad tissue, or in a mesonephric cell line (M15) that expresses endogenous WT1. These studies were done using both polyclonal and monoclonal anti-WT1 antibodies and, in each case, the anti-WT1 antibodies specifically labelled the nucleus in a characteristic punctate pattern, as well as giving a more diffuse nucleoplasmic staining, excluding nucleoli. Double-labelling experiments using antibodies that recognize other zinc-finger transcription factors, such as SP1, showed that there is a major difference between the staining patterns for the two proteins. Although both antibodies show diffuse nucleoplasmic labelling and both stain punctate structures, these punctate structures are distinct. In contrast, double labelling with anti-WT1 and anti-snRNP antibodies showed extensive co-localization, with both antibodies staining the same punctate structures, although the diffuse nucleoplasmic staining was stronger with the anti-WT1 antibodies than with the anti-snRNP antibodies (Fig. 2) .
The major subunits of active splicing complexesspliceosomes -are the U1, U2, U4/U6 and U5 small nuclear ribonucleoprotein particles (snRNPs). Spliceosomes form through the stepwise assembly of snRNPs and additional non-snRNP protein-splicing factors on mRNA precursor transcripts, and catalyze the removal of introns. In vivo, most splicing is believed to occur cotranscriptionally. Immunofluorescence localization studies, using antibodies specific for snRNP antigens, have revealed a complex snRNP staining pattern that includes at least three components (reviewed in [7, 8] ; compare with Fig. 2 ).
The first component of the snRNP-staining pattern is a widespread, diffuse staining that disappears if transcription is inhibited. It is likely that this widespread staining includes the bulk of snRNPs involved in cotranscriptional splicing. Nascent transcripts emerging from chromatin can be seen at the electron microscopic (EM) level as perichromatin fibrils. The other two components of the snRNP-staining pattern seen by fluorescence microscopy appear as numerous, irregular-shaped speckles and several bright round foci, forming a characteristic punctate pattern. At the EM level, the speckles correspond to clusters of interchromatin granules, whereas the foci correspond to coiled bodies. The new data from Larsson et al. [6] show that WT1 co-localizes with snRNPs in both interchromatin granule clusters and coiled bodies. Neither of these punctate structures are now believed to be major sites of splicing per se. The functions of coiled bodies and interchromatin granules remain to be established, but may include roles in snRNP maturation and assembly, recycling after splicing, and RNA transport or storage.
It is known that the snRNP staining pattern is highly dynamic and is affected by treatments that influence cellular gene expression. Both the WT1 and snRNP staining patterns were observed to change following Fig. 2 . Antibodies that recognize either WTI or splicing snRNPs show a similar punctate staining pattern. This pattern comprises labelling of coiled bodies (red), clusters of interchromatin granules (blue) and a diffuse, widespread nucleoplasmic component that excludes nucleoli (grey). The diffuse component is more prominent for WT1 than for snRNPs, and most transcription and splicing takes place over this region. As discussed in the text, both WT1 and snRNP staining patterns change if gene expression is inhibited.
microinjection of M15 cells with DNA oligonucleotides that were complementary to either the U1 or U6 snRNAs [6] . These oligonucleotides promote cleavage of the complementary snRNAs by endogenous RNaseH, and hence inhibit splicing. It has previously been shown that this results in a redistribution of snRNP antigens into large nucleoplasmic aggregates [9] , and a similar redistribution of WT1 has now been observed [6] .
It has been shown previously that inhibition of transcription by actinomycin D results in a loss of the diffuse snRNP staining, and loss of coiled bodies, with a concomitant clustering of most snRNP antigens into large nucleoplasmic aggregates of interchromatin granules. In addition, the coiled body protein, p80 coilin, and a subset of snRNP antigens form smaller foci that cluster around the periphery of the nucleolus and nucleolar remnants [10] . Double-labelling studies in M15 cells showed that WT1 specifically relocalized into the same perinucleolar structures that contain p80 coilin, but not into the nucleoplasmic snRNP clusters, following treatment with actinomycin D [6] . Together, these data confirm the in vivo association of WT1 with structures containing splicing snRNPs, and further indicate that WT1 can preferentially localize with a complex containing p80 coilin and a subset of splicing components following actinomycin D treatment.
The association of WT1 with splicing snRNPs was also confirmed biochemically using coimmunoprecipitation assays with nuclear extracts prepared from M15 cells. Antibodies specific for the common (Sm-type) snRNP antigens, and antibodies specific for proteins unique to either the Ul or U2 snRNP particles, all coimmunoprecipitated WT1. Interestingly, WT1 was also coimmunoprecipitated by antibodies specific for the coiled-body protein, p80 coilin. These antibodies selectively stain coiled bodies, but not interchromatin granule clusters, when used for immunofluorescence. An antibody specific for the transcription factor SP1 did not coprecipitate WT1.
When the immunoprecipitation assays were repeated using nuclear extracts prepared from M15 cells that were treated with actinomycin D, WT1 was still coimmunoprecipitated by anti-p80 coilin antibodies, but not by anti-Sm antibodies. In parallel controls, actinomycin D did not prevent direct immunoprecipitation of WT1 by anti-WT1 antibodies and did not result in coimmunoprecipitation of WT1 by anti-SP1 antibodies. Although these studies do not provide a quantitative measure of the extent of interaction between WT1 and splicing snRNPs, they correlate very closely with the immunofluorescence data. These findings indicate that WT1 is present in a common complex with splicing snRNPs and are consistent with WT1 interacting directly with snRNPs. The results also point to an interaction between WT1 and the coiled-body protein, p 8 0 coilin, which remains even when transcription is blocked by actinomycin D treatment.
As indicated above, the DNA-binding activity of WT1 was known to differ between isoforms that either have, or lack, the KTS insertion between zinc fingers 3 and 4. To address whether the four separate WT1 isoforms have similar, or different, nuclear localization patterns, Larsson et al. [6] examined each isoform individually by transient transfection in COS7 cells, which do not express endogenous WT1. These experiments showed that the localization was largely (but not completely) splice-form dependent. More specifically, there was a strong correlation between expression of isoforms that contained the KTS insert and co-localization with snRNPs. In contrast, preferential co-localization with snRNPs was not influenced by the presence or absence of the alternatively spliced exon 5.
Transient expression of genes encoding either the SP1 or PAX6 transcription factors in COS7 cells showed that both these proteins also localized to punctate subnuclear domains, but these domains did not co-localize with snRNPs and were labelled strongly by antibodies that recognize the endogenous basal transcription factor TFIIB. Interestingly, these SP1/PAX6 domains showed a preferential co-localization with the WT1 isoforms lacking the KTS insert, which in turn show less frequent overlap with snRNP-containing structures.
The localization data, while complicated in detail, point to a rather simple general conclusion: the presence or absence of the KTS insert between zinc fingers 3 and 4 of WT1 not only influences its affinity for binding DNA, but also has a dramatic effect upon the distribution of WT1 within the nucleus. Thus, the distribution of WT1 in tissues is likely to represent a composite of several distinct labelling patterns, in which the separate isoforms distribute differentially. This provides a clear example of how alternative splicing can modulate intranuclear protein localization. The fact that the most abundant isoforms of WT1 preferentially localize to subnuclear domains containing splicing snRNPs suggests that the view that it is primarily a transcription factor may have to be revised. Instead, a role for WT1 in either splicing, or some other aspect of RNA metabolism, appears a strong possibility.
As is usual with interesting discoveries, the new data on WT1 raise many more questions than they answer. For example, does WT1 have dual roles in transcription and RNA processing, mediated by separate isoforms? There are precedents for proteins, such as TFIIIA, that can bind in vivo to both DNA and RNA through a zinc finger motif. The differential distribution of WT1 isoforms may have profound significance for understanding the underlying causes of developmental abnormalities that can arise in patients with altered ratios of +KTS and -KTS isoforms. This could be due, at least in part, to an imbalance in the distribution of WT1 between splicing and transcription domains. It is possible, however, that the subset of WT1 associated with transcription domains could be involved in cotranscriptional splicing, rather than DNA binding and transcription. In this case the primary role of WT1 could be connected with splicing snRNPs. A detailed study of the RNA binding activity of WT1 isoforms will now be important. It will also be important to establish whether WT1 interacts directly with snRNP particles and whether it is present in active spliceosomes.
The WT1 protein is clearly not an obligatory splicing factor, as it is only expressed in restricted cell types. However, it could well have a function in regulating splicing in these cells and this needs to be addressed biochemically. The reason for the association of WT1 with coiled bodies and with the coiled-body protein, p80 coilin, even when snRNPs have dissociated from the coiled body following inhibition of transcription, presents another interesting line of investigation. The coiled body is a conserved snRNP domain found in both plant and animal cells, but its function remains unknown (reviewed in [8] ). Future studies on WT1 could offer some clues as to the role of the coiled body and will hopefully clarify whether the tumour suppressor activity of WT1 is exerted at the post-transcriptional level. If this is the case, we may look forward to important new insights into the role of RNA processing mechanisms in cellular growth control and oncogenesis.
